Over the past few years, several preclinical studies have highlighted the value of CD73 (ecto-5′-nucleotidase) as a potential therapeutic target for cancer therapy. Indeed, the pharmacological blockade of CD73, via monoclonal antibodies or small molecules, has promise in counteracting cancer development, growth and spread. Synergistic combinations of anti-CD73 drugs with conventional cancer treatments (i.e., chemotherapy, radiation therapy, immunotherapy, targeted therapy) have increased therapeutic potential. In this review, we discuss the potential synergistic effects of CD73 blockers and conventional antineoplastic therapies in the treatment of cancer.

在过去的几年中，一些临床前研究强调了CD73（ecto-5'-核苷酸酶）作为癌症治疗的潜在治疗靶标的价值。实际上，通过单克隆抗体或小分子对CD73的药理学阻断有望抵消癌症的发展，生长和扩散。抗CD73药物与常规癌症治疗（即化学疗法，放射疗法，免疫疗法，靶向疗法）的协同组合具有增加的治疗潜力。在这篇综述中，我们讨论了CD73受体阻滞剂和常规抗肿瘤疗法在治疗癌症中的潜在协同作用。